(Q34327488)

1 August 2017

title

Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents (English)

1 reference

1 August 2017

1 reference

Rudolph M Navari

1

1 reference

1 August 2017

publication date

1 March 2013

1 reference

1 August 2017

1 reference

1 August 2017

volume

73

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

249-262

1 reference

Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Aprepitant: a review of its use in the prevention of nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Whole brain radiotherapy with radiosensitizer for brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Antiemetics: American Society of Clinical Oncology clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Neurons in the nucleus of the solitary tract mediating inputs from emetic vagal afferents and the area postrema to the pattern generator for the emetic act in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Delayed emesis: moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Potential of substance P antagonists as antiemetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemothe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Identification and functional characterization of brainstem cannabinoid CB2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Anti‐emetic effect of ginger powder versus placebo as an add‐on therapy in children and young adults receiving high emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Prevention of emesis from multiple-day and high-dose chemotherapy regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0019-1

Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects

21 January 2018

1 reference

12 December 2020

Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study

1 reference

12 December 2020

1 reference

12 December 2020

Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities

1 reference

12 December 2020

Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.

1 reference

12 December 2020

[Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer]

1 reference

12 December 2020

Incidence of chemotherapy-induced nausea and emesis after modern antiemetics

1 reference

12 December 2020

Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study

1 reference

12 December 2020

Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function

1 reference

12 December 2020

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cispla

1 reference

12 December 2020

[Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP]

1 reference

12 December 2020

Why Do We Need Another Antiemetic? Just Ask

1 reference

12 December 2020

Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.

1 reference

12 December 2020

Antipsychotic-induced weight gain: a review of the literature

1 reference

12 December 2020

New treatment options for chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment

1 reference

12 December 2020

Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study

1 reference

12 December 2020

Organization of vestibular inputs to nucleus tractus solitarius and adjacent structures in cat brain stem

1 reference

12 December 2020

10.1007/S40265-013-0019-1

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1025059057

0 references

1 reference